HCPCS Level II code J3285 denotes the injection of treprostinil, billed per 1 mg, a prostacyclin analog used in treating pulmonary arterial hypertension and other vascular conditions. Nationally, this drug code matters because it represents a high-cost, specialty parenteral therapy administered across outpatient infusion centers, hospital outpatient departments, and ambulatory settings, impacting payer coverage policies and site-of-service cost differentials.

Key payers addressed in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines what readers will learn about coding and billing considerations for J3285, payer coverage patterns, common sites of service where the drug is administered, and how this code is recorded on medical claims. The summary highlights available benchmarks and policy context where present; where input data is not provided, the text notes that specific details are not available.

Readers will find a concise clinical context for treprostinil injections, typical billing scenarios, and a roadmap to the sections that follow covering modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service-line considerations. Data not available in the input is identified as such in the detailed sections.